Horm Metab Res 2022; 54(04): 220-223
DOI: 10.1055/a-1773-1127
Original Article: Endocrine Care

Diagnostic Utility of Procalcitonin for Sporadic Medullary Thyroid Carcinoma in Patients with Nodular Disease and Mild or Moderate Hypercalcitoninemia

1   Faculdade Santa Casa de Belo Horizonte, Minas Gerais, Brazil
,
Gabriela Franco Mourão
1   Faculdade Santa Casa de Belo Horizonte, Minas Gerais, Brazil
› Author Affiliations
Funding Information This work was supported by the National Council for Scientific and Technological Development (CNPq).

Abstract

Many authors recommend the measurement of serum calcitonin (Ctn) to screen for sporadic medullary thyroid carcinoma (MTC) in patients with thyroid nodules. In this situation, procalcitonin (pro-Ctn) would have greater utility in patients with hypercalcitoninemia<100 pg/ml. The aim of this study was to evaluate the utility of pro-Ctn in patients with thyroid nodules and without a suspicion of familial MTC or type 2 multiple endocrine neoplasia who had mild or moderate hypercalcitoninemia without an apparent cause. Consecutive patients with nodular thyroid disease assessed routinely by Ctn measurement were selected. Sixty patients with basal Ctn>10 pg/ml but<100 pg/ml were included. Nine patients (15%) had MTC, with cytology being diagnostic in only four. Among the 51 patients without MTC, pro-Ctn was<0.1 ng/ml in 46 (90.2%). All patients with MTC had pro-Ctn>0.1 ng/ml. Basal Ctn was>24.6 pg/ml in all patients with MTC and in 42 patients (82.3%) without MTC. It is noteworthy that among patients with basal Ctn>24.6 pg/ml (n=18) pro-Ctn>0.1 ng/ml identified all patients with MTC and 64.2% of subjects with these pro-Ctn concentrations had this tumor. In conclusion, we did not find superiority of pro-Ctn over Ctn for the diagnosis of sporadic MTC in patients with nodular disease and mild or moderate hypercalcitoninemia. However, in the case of patients with hypercalcitoninemia in the gray zone, pro-Ctn has an excellent negative predictive value while the data regarding its positive predictive value are not uniform.



Publication History

Received: 12 January 2022

Accepted after revision: 09 February 2022

Article published online:
12 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Giovanella L, Garo ML, Ceriani L. et al. Procalcitonin as an alternative tumor marker of medullary thyroid carcinoma. J Clin Endocrinol Metab 2021; 106: 3634-3643
  • 2 Algeciras-Schimnich A, Preissner CM, Theobald JP. et al. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2009; 94: 861-868
  • 3 Machens A, Lorenz K, Dralle H. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. J Clin Endocrinol Metab 2014; 99: 2986-2994
  • 4 Lim SK, Guéchot J, Vaubourdolle M. Negative predictive value of procalcitonin in medullary thyroid carcinoma. Ann Biol Clin (Paris) 2016; 74: 213-218
  • 5 Censi S, Di Stefano M, Repaci A. et al. Basal and calcium-stimulated procalcitonin for the diagnosis of medullary thyroid cancers: lights and shadows. Front Endocrinol (Lausanne) 2021; 12: 754565
  • 6 Rosario PW, Mourão GF, Calsolari MR. Basal serum calcitonin, after calcium stimulation, and in the needle washout of patients with thyroid nodules and mild or moderate basal hypercalcitoninemia. Horm Metab Res 2017; 49: 129-134
  • 7 https://www.biomerieux-diagnostics.com/vidasr-brahms-pct
  • 8 Giovanella L, Verburg FA, Imperiali M. et al. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules. Clin Chem Lab Med 2013; 51: 1477-1481
  • 9 Giovanella L, Imperiali M, Piccardo A. et al. Procalcitonin measurement to screen medullary thyroid carcinoma: A prospective evaluation in a series of 2705 patients with thyroid nodules. Eur J Clin Invest 2018; 48: e12934
  • 10 Giovanella L, Fontana M, Keller F. et al. Clinical performance of calcitonin and procalcitonin Elecsys immunoassays in patients with medullary thyroid carcinoma. Clin Chem Lab Med 2020; 59: 743-747